Inotuzumab Ozogamacin

Introduction

Inotuzumab Ozogamacin is a targeted cancer therapy used primarily to treat adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). This monoclonal antibody-drug conjugate combines an antibody that targets the CD22 antigen on leukemia cells with a cytotoxic agent. It is designed to deliver the chemotherapy drug directly to cancerous cells, thereby reducing the impact on healthy tissues. Inotuzumab Ozogamacin is administered intravenously under medical supervision and is known for its precision in targeting and destroying malignant cells with fewer systemic effects compared to conventional chemotherapy.

Uses of Inotuzumab Ozogamacin

• Treatment of B-cell precursor acute lymphoblastic leukemia (ALL)
• Used in adults with relapsed or refractory ALL
• May be considered prior to stem cell transplantation

How Inotuzumab Ozogamacin works

Inotuzumab Ozogamacin works by binding to the CD22 antigen present on the surface of B-cell leukemia cells. Once attached, the conjugated chemotherapy drug is internalized into the cancer cell, where it releases a cytotoxic agent that breaks the DNA strands, resulting in cell death. This targeted mechanism allows for higher efficacy with reduced damage to healthy cells.

Benefits of Inotuzumab Ozogamacin

• Targeted therapy with reduced systemic toxicity
• Improves remission rates in relapsed or refractory ALL
• Facilitates eligibility for stem cell transplantation
• Administered in a hospital setting for close monitoring

How to take Inotuzumab Ozogamacin

Inotuzumab Ozogamacin is given by intravenous (IV) infusion under the supervision of an oncologist. The dosage is usually calculated based on body surface area and administered over a cycle of 21 days. Your healthcare provider will monitor liver function, blood counts, and other vital parameters throughout treatment. Do not self-administer this medication.

Type of Dosage Available

• Intravenous injection (IV infusion)

Side effects of Inotuzumab Ozogamacin

• Fatigue
• Nausea and vomiting
• Fever
• Low blood cell counts (anemia, thrombocytopenia)
• Increased liver enzymes or liver damage
• Infusion-related reactions
• Veno-occlusive disease (serious liver condition)

Safety advice

• Administer only under the supervision of a qualified healthcare provider
• Regular liver function tests and blood counts are essential
• Avoid live vaccines during treatment
• Inform your doctor of any pre-existing liver conditions
• Use effective contraception during treatment and for some time after

Frequently Asked Questions (FAQs)

Q: What is Inotuzumab Ozogamacin used for?
A: It is used to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

Q: How is Inotuzumab Ozogamacin administered?
A: It is given by intravenous infusion in a clinical setting under doctor supervision.

Q: What are the common side effects of Inotuzumab Ozogamacin?
A: Common side effects include nausea, fatigue, fever, and low blood cell counts.

Q: Is Inotuzumab Ozogamacin a form of chemotherapy?
A: Yes, it is a targeted chemotherapy drug that binds to leukemia cells to deliver cytotoxic agents directly.

Q: Can Inotuzumab Ozogamacin be used in children?
A: It is primarily approved for adult patients. Pediatric use should be discussed with a specialist.